Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Lymphangioleiomyomatosis × Letrozole × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 153 Polycystic Ovary Syndrome 18 Neoplasm Metastasis 9 Osteoporosis 6 Neoplasms 5 Endometrial Neoplasms 5 Ovarian Neoplasms 4 Infertility 4 Carcinoma, Intraductal, Noninfiltrating 4 Arthralgia 4 Hereditary Sensory and Autonomic Neuropathies 3 Carcinoma, Ductal, Breast 3 Breast Neoplasms, Male 3 Breast Carcinoma In Situ 3 Breast Cancer Metastatic 3 Triple Negative Breast Neoplasms 2 Recurrence 2 Pain 2 Leiomyoma 2 Fallopian Tube Neoplasms 2 Carcinoma, Lobular 2 Advanced Breast Cancer 2 Uterine Neoplasms 1 Patient Acceptance of Health Care 1 Ovarian Cysts 1 Osteitis Deformans 1 Obesity 1 Neoplastic Cells, Circulating 1 Neoplasms, Hormone-Dependent 1 Neoplasm, Residual 1

Interventions

Sirolimus 6 Everolimus 3 saracatinib 1 Urination 1 Sugars 1 Simvastatin 1 Resveratrol 1 Octreotide 1 Letrozole 1 Imatinib Mesylate 1 Hydroxychloroquine 1 Doxycycline 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01353209 2024-04-17

TRAIL

University of Cincinnati

Phase 2 Completed

17 enrolled 13 charts

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡